CanPathPro · Project

Cancer Drug Response Prediction Platform Using Patient Data and Pathway Modeling

healthPrototypeTRL 5

Imagine trying to figure out why a cancer drug works for one patient but not another. Right now, researchers look at bits and pieces — one gene here, one protein there — like reading a single page of a thousand-page mystery novel. CanPathPro built a computer platform that reads the whole book at once, mapping how cancer signals bounce around inside cells and predicting which drugs will actually shut them down. They combined lab experiments in mice with mathematical models so doctors and drug companies can test their ideas before touching a real patient.

By the numbers

consortium partners

countries represented

SMEs involved in commercialization

total project deliverables

30%

industry partner ratio in consortium

The business problem

What needed solving

Cancer drug development is plagued by late-stage failures because existing tools analyze individual pathways in isolation, missing the complex cross-talk that determines whether a tumor responds to treatment or resists it. Companies spend years and millions on candidates that look promising in narrow tests but fail when the full biological picture is considered. There is no systematic tool that evaluates personalized medicine approaches at the preclinical level before committing to expensive clinical trials.

The solution

What was built

The project built a combined experimental and computational platform for predictive cancer pathway modeling. Concrete outputs include a web-based platform interface for external users to access the analysis pipeline, an integrated systems biology model combining NGS and quantitative proteomics data, and a controlled mouse experimental validation system.

Audience

Who needs this

Pharma companies with oncology drug pipelines struggling with late-stage trial failuresBiotech SMEs offering omics data analysis services looking for predictive modeling capabilitiesContract research organizations running preclinical cancer studiesCompanion diagnostics companies developing personalized treatment selection toolsAcademic medical centers building precision oncology programs

Business applications

Who can put this to work

Pharmaceuticals

enterprise

Target: Mid-to-large pharma companies with oncology pipelines

If you are a pharma company spending years on cancer drug candidates that fail in late-stage trials — this project developed an integrated experimental and computational platform that models cancer signaling pathways and predicts drug response before clinical testing. With 10 consortium partners across 6 countries validating the approach, the platform could help you screen compounds earlier and cut preclinical dead ends.

Biotech & Diagnostics

SME

Target: Biotech SMEs offering omics data analysis or companion diagnostics

If you are a biotech company working with genomic or proteomic data but struggling to turn complex datasets into actionable treatment predictions — CanPathPro built a systems biology platform specifically for interpreting omics data and generating testable hypotheses. The consortium included 3 SMEs developing commercial applications, and a web-based interface was built for external users to access the pipeline.

Contract Research Organizations

mid-size

Target: CROs providing preclinical oncology services

If you are a CRO running preclinical cancer studies and need better tools to evaluate personalized medicine approaches — this project developed a controlled mouse experimental system combined with NGS and quantitative proteomics readouts integrated into a predictive model. The platform was designed to be made available to researchers, SMEs, and industry for practical applications.

Frequently asked

Quick answers

What would it cost to access or license this platform?

Based on available project data, pricing is not disclosed. The project objective states that a commercial platform for omics data interpretation was planned to be set up by participating companies after the project. Contact the coordinator ALACRIS THERANOSTICS GMBH for licensing terms.

Can this platform handle industrial-scale drug screening datasets?

The platform integrates NGS data, quantitative proteomics, and systems biology modeling into a single pipeline. A web-based interface was built for external users to interact with the pipeline. However, throughput benchmarks for industrial-scale screening volumes are not specified in the available data.

Who owns the IP and how is it licensed?

The project was coordinated by ALACRIS THERANOSTICS GMBH, a German SME, with 3 industry partners among 10 total consortium members. The objective explicitly states the tools will be made available to researchers, SMEs, and industry. Specific IP arrangements should be discussed directly with the coordinator.

Has this been validated with real patient or clinical data?

The project used controlled mouse experimental systems with NGS and quantitative proteomics for validation. The objective describes generating testable hypotheses and experimentally validating them. Translation to clinical practice was identified as a next step rather than a completed milestone.

How does this integrate with existing lab information systems?

A webpage platform was set up as the interface between user/client and the computational pipeline. Based on available project data, specific integration capabilities with third-party LIMS or EHR systems are not detailed. The web-based architecture suggests API connectivity would be technically feasible.

What is the timeline to deploy this in our R&D workflow?

The project ran from 2016 to 2021 and produced a prototype platform with a web interface. Since the consortium planned commercial deployment after the project, current deployment readiness should be verified with ALACRIS THERANOSTICS. The platform would likely require customization for specific drug discovery workflows.

Consortium

Who built it

The CanPathPro consortium brings together 10 partners from 6 countries (Germany, France, Spain, Netherlands, Norway, Switzerland), with a strong research backbone of 6 research organizations and 1 university. For a business buyer, the key signal is that 3 of the 10 partners are SMEs, including the coordinator ALACRIS THERANOSTICS GMBH — a German theranostics company that clearly has commercial intent. The 30% industry ratio and SME-led coordination suggest this was built with market application in mind, not just academic publication. The multi-country spread across major European biotech hubs adds credibility and potential for cross-border deployment.

ALACRIS THERANOSTICS GMBHCoordinator · DE
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBHparticipant · DE
SIMULA RESEARCH LABORATORY ASparticipant · NO
FINOVATISparticipant · FR
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICASparticipant · ES
RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONNparticipant · DE
CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET EN MEDECINEparticipant · FR
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUISparticipant · NL
LEIBNIZ-INSTITUT FUR ALTERNSFORSCHUNG - FRITZ-LIPMANN-INSTITUT EV (FLI) LEIBNIZ INSTITUTE ON AGING - FRITZ LIPMANN INSTITUTE EV (FLI)participant · DE

How to reach the team

ALACRIS THERANOSTICS GMBH is a German SME specializing in theranostics — reach out to their business development team for licensing or partnership discussions.

Order a report on this consortium See ALACRIS THERANOSTICS GMBH profile →

Next steps

Talk to the team behind this work.

Want an introduction to the CanPathPro team? SciTransfer can connect you with the right person and prepare a tailored briefing on how this platform fits your drug discovery pipeline.

Order a report on this topic More in Health & Biomedical